Genotarget, a startup belonging to Artgen Biotech, has completed preclinical studies of a new gene therapy drug GTDF102 for the treatment of muscular dystrophy. In studies conducted on mice with a disease model, it was possible to achieve the synthesis of the normal protein dysferlin in an amount sufficient to improve the condition of muscle tissue. Genotarget will now submit a dossier to the Ministry of Health to obtain approval to conduct clinical trials of the drug with patients.